Pharmaceutical

CNS market resurgence: a decade-long slump ends with $80bn milestone

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround.

Apr 2, 2025 - 06:00
CNS market resurgence: a decade-long slump ends with $80bn milestone
In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround.
Read the original article

Tags:

Previous Article

Magazine: Are European biopharma manufacturers ‘nearshoring’?

Next Article

Judge rejects J&J’s $9bn talc settlement for third time

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biocytogen and Radiance partner for bispecific antibody-drug conjugate

Biocytogen and Radiance partner for bispecific antibody...

Jan 9, 2024

CMS sets up negotiating framework for expensive sickle cell disease gene therapies

CMS sets up negotiating framework for expensive sickle ...

Jan 31, 2024

Keytruda remains Merck & Co’s biggest 2023 success story as patent expiry looms

Keytruda remains Merck & Co’s biggest 2023 success stor...

Feb 2, 2024